Ensysce Biosciences, Inc. filed 3 current reports with the SEC under Item 5.02, which covers directors and officers leaving or being appointed, the latest on 2026-08-06. Between them they name 2 people, with 1 appointment and 1 departure. Each change below is quoted from the filing and linked to it.
Every change, newest first
Departing: Lynn Kirkpatrick, President
Resignation of Lynn Kirkpatrick as President and Appointment of James Morrison as President and Director Pursuant to the Merger Agreement, on August 5, 2026, Lynn Kirkpatrick resigned from her position as President of the Company, effective immediately upon the Closing.
Appointed: James Morrison, President
Appointment of James Morrison as President and Director Pursuant to the Merger Agreement, on August 4, 2026, the Board, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed James Morrison as President and as a director of the Company effective immediately upon the Closing and appointed Mr. Morrison as Chief Executive Officer effective upon approval of the Meeting Proposals.
Reported
On April 1, 2026, Ensysce Biosciences Inc. (the "Company") received a resignation notice, dated and effective April 1, 2026, from Curtis Rosebraugh, a member of our Board of Directors.
Reported
On March 24, 2026, Ensysce Biosciences Inc. (the "Company") received a resignation notice, dated and effective March 24, 2026, of Lee Rauch, a member of our Board of Directors.
Find people with the same kind of experience as the President at Ensysce Biosciences, Inc., with the record behind each one.
Find candidates like President at Ensysce Biosciences, Inc.New leaders review vendors and budgets in their first months. Get an alert the next time Ensysce Biosciences, Inc. is in the news or changes leadership.
Get an alert when Ensysce Biosciences, Inc. changes leadershipTools for this story
Each opens in a new tab, filled in for Ensysce Biosciences, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.